CELL INTELLIGENCE · 肿瘤细胞治疗研究

晚期胃食管腺癌的当前及新兴靶向治疗

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma.

IMM2510，一种用于癌症免疫治疗的新型抗 PD-L1/VEGF 双特异性抗体

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.

IMM2510 结合了检查点阻断、抗血管生成、Fc 介导的效应功能以及协同结合，从而在多种肿瘤环境中展现出优越的临床前抗肿瘤活性。这些发现使 IMM2510 成为具有差异化特征的新一代治疗候选药物，适合进行临床开发。

胃癌中的抗体介导治疗：过去、现在与未来

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future.

超越检查点抑制：保持治疗选择开放

Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open.

胃癌的靶向治疗与免疫治疗：合理策略、新进展、挑战与未来展望

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.

血液系统恶性肿瘤中靶向 ROR1 的治疗进展

Therapeutic advances in the targeting of ROR1 in hematological cancers.

同时靶向抗 TGF-β/VEGF 双特异性抗体与 PD-1 阻断在癌症治疗中的协同疗效

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.

Y332D 可同时阻断 TGF-β和 VEGF 信号通路。与单药治疗相比，Y332D 联合 PD-1 阻断通过改善免疫微环境发挥更优的抗肿瘤效果。

VEGFR2 靶向多柔比星免疫脂质体与 NK 细胞活化协同增强抗肿瘤及抗转移作用

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation.

靶向肿瘤血管以改善经体外 T 细胞衔接双特异性抗体武装的 T 细胞的抗肿瘤活性

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.

αVEGFR2-MICA 融合抗体增强免疫治疗效应并与 PD-1 阻断产生协同作用

αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.